TW202045203A - 子癇前症之治療方法 - Google Patents
子癇前症之治療方法 Download PDFInfo
- Publication number
- TW202045203A TW202045203A TW109104126A TW109104126A TW202045203A TW 202045203 A TW202045203 A TW 202045203A TW 109104126 A TW109104126 A TW 109104126A TW 109104126 A TW109104126 A TW 109104126A TW 202045203 A TW202045203 A TW 202045203A
- Authority
- TW
- Taiwan
- Prior art keywords
- antithrombin
- preeclampsia
- mmhg
- blood pressure
- administration
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 44
- 206010029164 Nephrotic syndrome Diseases 0.000 title abstract 7
- 208000009928 nephrosis Diseases 0.000 title abstract 7
- 231100001027 nephrosis Toxicity 0.000 title abstract 7
- 206010020772 Hypertension Diseases 0.000 title description 14
- 239000004019 antithrombin Substances 0.000 claims abstract description 210
- 230000000694 effects Effects 0.000 claims abstract description 52
- 239000000203 mixture Substances 0.000 claims abstract description 49
- 239000008280 blood Substances 0.000 claims abstract description 35
- 210000004369 blood Anatomy 0.000 claims abstract description 35
- 201000011461 pre-eclampsia Diseases 0.000 claims description 80
- 230000035487 diastolic blood pressure Effects 0.000 claims description 40
- 230000035488 systolic blood pressure Effects 0.000 claims description 39
- 108090000190 Thrombin Proteins 0.000 claims description 10
- 229960004072 thrombin Drugs 0.000 claims description 10
- 229950006372 antithrombin gamma Drugs 0.000 claims description 7
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 229940088598 enzyme Drugs 0.000 claims description 3
- 208000002296 eclampsia Diseases 0.000 claims description 2
- 230000010100 anticoagulation Effects 0.000 claims 1
- 206010070538 Gestational hypertension Diseases 0.000 abstract description 10
- 201000005624 HELLP Syndrome Diseases 0.000 abstract description 10
- 208000005347 Pregnancy-Induced Hypertension Diseases 0.000 abstract description 10
- 208000036335 preeclampsia/eclampsia 1 Diseases 0.000 abstract description 10
- 230000035935 pregnancy Effects 0.000 description 91
- 229940068196 placebo Drugs 0.000 description 45
- 239000000902 placebo Substances 0.000 description 45
- 238000001647 drug administration Methods 0.000 description 24
- 108090000935 Antithrombin III Proteins 0.000 description 17
- 102000009027 Albumins Human genes 0.000 description 15
- 108010088751 Albumins Proteins 0.000 description 15
- 230000001225 therapeutic effect Effects 0.000 description 15
- 102100022977 Antithrombin-III Human genes 0.000 description 10
- 238000012360 testing method Methods 0.000 description 9
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
- 102000004411 Antithrombin III Human genes 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 229960005348 antithrombin iii Drugs 0.000 description 6
- 208000011580 syndromic disease Diseases 0.000 description 6
- 230000015271 coagulation Effects 0.000 description 5
- 238000005345 coagulation Methods 0.000 description 5
- 230000001605 fetal effect Effects 0.000 description 5
- 238000010253 intravenous injection Methods 0.000 description 5
- 201000001474 proteinuria Diseases 0.000 description 5
- 239000004471 Glycine Substances 0.000 description 4
- 206010021143 Hypoxia Diseases 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 210000003754 fetus Anatomy 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 230000008774 maternal effect Effects 0.000 description 4
- 210000002826 placenta Anatomy 0.000 description 4
- 230000003169 placental effect Effects 0.000 description 4
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 4
- 208000028399 Critical Illness Diseases 0.000 description 3
- 206010035138 Placental insufficiency Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 2
- 102100022641 Coagulation factor IX Human genes 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 108010076282 Factor IX Proteins 0.000 description 2
- 108010074860 Factor Xa Proteins 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102100035194 Placenta growth factor Human genes 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000002220 antihypertensive agent Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- 239000003130 blood coagulation factor inhibitor Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 206010008129 cerebral palsy Diseases 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229960004222 factor ix Drugs 0.000 description 2
- 230000020764 fibrinolysis Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 230000001146 hypoxic effect Effects 0.000 description 2
- 230000008816 organ damage Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000009984 peri-natal effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 230000036266 weeks of gestation Effects 0.000 description 2
- PYHRZPFZZDCOPH-QXGOIDDHSA-N (S)-amphetamine sulfate Chemical compound [H+].[H+].[O-]S([O-])(=O)=O.C[C@H](N)CC1=CC=CC=C1.C[C@H](N)CC1=CC=CC=C1 PYHRZPFZZDCOPH-QXGOIDDHSA-N 0.000 description 1
- 201000005657 Antithrombin III deficiency Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 102100037241 Endoglin Human genes 0.000 description 1
- 108010036395 Endoglin Proteins 0.000 description 1
- 241000160765 Erebia ligea Species 0.000 description 1
- 108010048049 Factor IXa Proteins 0.000 description 1
- 108010014173 Factor X Proteins 0.000 description 1
- 108010074864 Factor XI Proteins 0.000 description 1
- 108010080865 Factor XII Proteins 0.000 description 1
- 102000000429 Factor XII Human genes 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000757319 Homo sapiens Antithrombin-III Proteins 0.000 description 1
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 description 1
- 108060005987 Kallikrein Proteins 0.000 description 1
- 102000001399 Kallikrein Human genes 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000001300 Perinatal Death Diseases 0.000 description 1
- 108010082093 Placenta Growth Factor Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 201000009454 Portal vein thrombosis Diseases 0.000 description 1
- 206010036877 Prolonged Pregnancy Diseases 0.000 description 1
- 229940122055 Serine protease inhibitor Drugs 0.000 description 1
- 101710102218 Serine protease inhibitor Proteins 0.000 description 1
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 1
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 108010072035 antithrombin III-protease complex Proteins 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical class [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 235000021310 complex sugar Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000004578 fetal growth Effects 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 208000033666 hereditary antithrombin deficiency Diseases 0.000 description 1
- 102000052834 human SERPINC1 Human genes 0.000 description 1
- 229960004336 human antithrombin iii Drugs 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 208000018773 low birth weight Diseases 0.000 description 1
- 231100000533 low birth weight Toxicity 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 238000009522 phase III clinical trial Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 208000012113 pregnancy disease Diseases 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000003001 serine protease inhibitor Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940035247 thrombate iii Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962803888P | 2019-02-11 | 2019-02-11 | |
| US62/803,888 | 2019-02-11 | ||
| US201962820459P | 2019-03-19 | 2019-03-19 | |
| US62/820,459 | 2019-03-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202045203A true TW202045203A (zh) | 2020-12-16 |
Family
ID=72044881
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW109104126A TW202045203A (zh) | 2019-02-11 | 2020-02-11 | 子癇前症之治療方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20220202920A1 (https=) |
| EP (1) | EP3925616A4 (https=) |
| JP (2) | JPWO2020166557A1 (https=) |
| AU (1) | AU2020222120A1 (https=) |
| CA (1) | CA3129755A1 (https=) |
| TW (1) | TW202045203A (https=) |
| WO (1) | WO2020166557A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021112606A1 (ko) | 2019-12-05 | 2021-06-10 | 주식회사 엘지에너지솔루션 | 리튬 이차전지용 양극 활물질, 상기 양극 활물질의 제조 방법 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07316072A (ja) * | 1994-05-24 | 1995-12-05 | Green Cross Corp:The | 妊娠中毒症治療剤 |
| CN1890262B (zh) | 2003-10-09 | 2015-01-28 | 协和发酵麒麟株式会社 | 抗凝血酶ⅲ组合物的制造方法 |
| WO2008120801A1 (ja) | 2007-04-02 | 2008-10-09 | Kyowa Hakko Kirin Co., Ltd. | アンチトロンビン組成物の製造方法 |
| US20180104318A1 (en) * | 2015-03-31 | 2018-04-19 | Kyowa Hakko Kirin Co., Ltd. | Therapeutic composition containing antithrombin gamma |
-
2020
- 2020-02-10 JP JP2020572244A patent/JPWO2020166557A1/ja active Pending
- 2020-02-10 CA CA3129755A patent/CA3129755A1/en active Pending
- 2020-02-10 AU AU2020222120A patent/AU2020222120A1/en not_active Abandoned
- 2020-02-10 WO PCT/JP2020/005130 patent/WO2020166557A1/ja not_active Ceased
- 2020-02-10 US US17/429,887 patent/US20220202920A1/en not_active Abandoned
- 2020-02-10 EP EP20755567.3A patent/EP3925616A4/en not_active Withdrawn
- 2020-02-11 TW TW109104126A patent/TW202045203A/zh unknown
-
2023
- 2023-02-28 JP JP2023029934A patent/JP2023060011A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3925616A4 (en) | 2022-12-21 |
| AU2020222120A1 (en) | 2021-09-02 |
| JPWO2020166557A1 (ja) | 2021-12-16 |
| EP3925616A1 (en) | 2021-12-22 |
| JP2023060011A (ja) | 2023-04-27 |
| WO2020166557A1 (ja) | 2020-08-20 |
| CA3129755A1 (en) | 2020-08-20 |
| US20220202920A1 (en) | 2022-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6878423B2 (ja) | プラスミノーゲン欠損症のためのプラスミノーゲン補充療法 | |
| Blanchard et al. | Effect of hydrochlorothiazide on urinary calcium excretion in dent disease: an uncontrolled trial | |
| CN107088225A (zh) | 治疗法布里病的给药方案 | |
| WO2011150393A2 (en) | Methods for improving maternal and fetal health | |
| TW201400499A (zh) | 抗凝血酶用於治療妊娠毒血症之用途 | |
| RU2508124C2 (ru) | Применение гиалуронидазы для профилактики или лечения артериальной гипертензии или сердечной недостаточности | |
| TW202045203A (zh) | 子癇前症之治療方法 | |
| CA2492858C (en) | Use of digoxin immune fab for the regulation of sodium/potassium atpase activity in preeclamptic and eclamptic patients | |
| Mercanti et al. | Ibubrofen in the treatment of patent ductus arteriosus in preterm infants: what we know, what we still do not know | |
| CN1688337B (zh) | 用于调节先兆子痫患者和子痫患者的钠/钾三磷酸腺苷酶活性的地高辛免疫fab的用途 | |
| BR112020017626A2 (pt) | Tratamento e prevenção de pré-eclâmpsia | |
| Kavanagh | Antihypertensive drugs | |
| KR20070014114A (ko) | 괴사성 장염의 치료 | |
| EP2961422A1 (en) | Therapeutic agent for amniotic fluid embolism | |
| Pisciotto | Neonatal plasma transfusions | |
| Steiner | Successful treatment of acrodermatitis enteropathica with zinc sulfate | |
| Brampton | PrRAN™-LISINOPRIL | |
| Chaudhry et al. | Hypertension In Pregnancy: A Review of Preecamplesia, Its Effects and Management | |
| Nobili et al. | Beta-Adrenoceptor Antagonists and Antianginal Drugs | |
| JP2014162789A (ja) | 羊水塞栓症治療剤 | |
| Manjula | Universal Screening With Glucose Challenge Test Using 75 Grams Glucose To Detect Gestational Diabetes Mellitus | |
| Al-Jeboury et al. | The role of low dose furesemide in reducing postpartum blood pressure among women with preeclampsia | |
| JP2000505819A (ja) | 製剤製品 |